U.S. Markets close in 1 hr 46 mins
  • S&P 500

    +59.10 (+1.81%)
  • Dow 30

    +319.62 (+1.21%)
  • Nasdaq

    +240.25 (+2.18%)
  • Russell 2000

    +13.15 (+0.85%)
  • Crude Oil

    -0.94 (-2.51%)
  • Gold

    -11.40 (-0.61%)
  • Silver

    +0.03 (+0.11%)

    -0.0086 (-0.7348%)
  • 10-Yr Bond

    +0.0550 (+7.04%)
  • Vix

    -4.28 (-10.63%)

    -0.0070 (-0.5425%)

    +0.3900 (+0.3739%)

    +390.23 (+2.97%)
  • CMC Crypto 200

    +24.36 (+10.04%)
  • FTSE 100

    -1.05 (-0.02%)
  • Nikkei 225

    -86.57 (-0.37%)

ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men

LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation.

The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future.

This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products.

Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period.

Company Update
The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's topical antibiotic uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com

Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.